EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Interpretable machine learning applied to high-dimensional salivary proteomics in pediatric inflammatory bowel diseases

Brittany T Rupp, Joaquin Reyna, Ally Giunta, Theresa Weaver, Kelly Chason, Jinze Liu, Ajay S Gulati, Kevin M Byrd

Inflammatory Bowel Diseases · 2026-11-09

DOI: 10.1093/ibd/izag181 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD), ulcerative colitis (UC), and inflammatory bowel disease unclassified (IBD-U), are chronic inflammatory disorders of the gastrointestinal tract. Current methods for classification and longitudinal monitoring are invasive, expensive, and often delayed, limiting timely diagnosis and management. This proof-of-concept study reports the first application of high-dimensional salivary proteomics integrated with interpretable artificial intelligence/machine learning (ML) to define a minimal protein signature for pediatric IBD classification with the ultimate goal of informing therapeutic decision-making. Methods Unstimulated saliva from pediatric CD, UC, and IBD-U patients was analyzed using Alamar Biosciences’ NULISAseq 250 Protein Inflammation Panel. Logistic regression with recursive feature elimination identified a candidate minimal discriminative signature. Performance was further assessed using follow-up samples. SHAP (SHapley Additive exPlanations) quantified patient-specific protein contributions and assessed biological similarity of IBD-U to CD and UC. Results Differential abundance analysis between UC and CD revealed 53 significantly different proteins. ML identified a 14-protein signature comprising chemokines/cytokines (CCL1, IFNA1-IFNA13, IL12p70, IL34, TNFSF11/RANKL), receptors/ligands (CD40LG, ICOSLG, IL1R2, IL17RA), structural/tissue-remodeling proteins (CD93, GFAP, SPP1), and growth factors/immune modulators (GDF2, GZMA). The proposed model achieved 97.5% balanced accuracy in first-visit pilot samples and 80.2% with matched follow-up samples. SHAP revealed patient-specific drivers and suggested biological alignment of IBD-U cases toward CD- or UC-like profiles. Conclusions This first-in-field integration of salivary proteomics with interpretable artificial intelligence/ML demonstrates that accurate, noninvasive classification of pediatric IBD is possible using minimal biomarker sets. This approach establishes a scalable framework for future longitudinal monitoring and supports earlier and more precise therapeutic interventions.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →